Charles Schwab Investment Management Inc. Has $8.79 Million Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Charles Schwab Investment Management Inc. increased its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 4.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,983,240 shares of the biotechnology company’s stock after purchasing an additional 78,969 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.24% of Ironwood Pharmaceuticals worth $8,786,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in IRWD. Pacer Advisors Inc. lifted its stake in Ironwood Pharmaceuticals by 4.0% in the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after acquiring an additional 450,949 shares during the last quarter. State Street Corp lifted its stake in Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock valued at $40,870,000 after acquiring an additional 677,024 shares during the last quarter. FMR LLC lifted its stake in Ironwood Pharmaceuticals by 25.1% in the third quarter. FMR LLC now owns 169,681 shares of the biotechnology company’s stock valued at $699,000 after acquiring an additional 34,089 shares during the last quarter. Weiss Asset Management LP acquired a new stake in Ironwood Pharmaceuticals in the third quarter valued at approximately $893,000. Finally, Walleye Capital LLC lifted its stake in Ironwood Pharmaceuticals by 264.2% in the third quarter. Walleye Capital LLC now owns 280,299 shares of the biotechnology company’s stock valued at $1,155,000 after acquiring an additional 203,331 shares during the last quarter.

Insider Buying and Selling

In related news, CMO Michael Shetzline sold 41,269 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

IRWD has been the subject of a number of analyst reports. Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. StockNews.com cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Finally, JMP Securities dropped their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.60.

Ironwood Pharmaceuticals Stock Down 7.8 %

NASDAQ:IRWD opened at $1.41 on Friday. Ironwood Pharmaceuticals, Inc. has a 12 month low of $1.34 and a 12 month high of $9.01. The firm has a market cap of $225.64 million, a price-to-earnings ratio of -47.00 and a beta of 0.37. The company’s 50 day moving average is $2.27 and its 200-day moving average is $3.49.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $90.55 million during the quarter, compared to the consensus estimate of $93.85 million. Research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.